Ackman Shoots Down Idea of Valeant (VRX) Unloading Bausch & Lomb

Pershing Square's Bill Ackman, speaking on CNBC late Thursday, said that Valeant Pharma (NYSE: VRX) isn't going to sell its Bausch & Lomb unit.

It's a core asset. We're only considering selling non-core assets, Ackman, who was recently appointed to Valeant's board, commented.

Ackman recently said on Pershing Square's Q1 conference call that Valeant's board was working expeditiously to find a replacement CEO for outgoing Mike Pearson, but that Pearson was doing a terrific job in the interim. Ackman believes a new CEO could be appointed within weeks, not months.

Shares of Valeant are indicated for a higher open Friday.

You May Also Be Interested In

• Regenxbio shares jump after FDA agrees to reverse drug rejection
• ClearPoint Neuro stock surges on peer's FDA approval plan
• Gildan responds to short seller report, reiterates 2026 guidance